COMPANY UPDATES
31
Oct
2018
Novoheart to Generate USD $1.7m From Strategic Partnership to Build Good Manufacturing Practice Facility to Create Clinical-Grade Human Stem Cell Libraries

Novoheart is pleased to announce that it has entered into a service agreement with Xellera Therapeutics Limited, representing Phase 1 of an intended long-term strategic partnership between the companies.

04
Oct
2018
Novoheart Showcase at Annual Safety Pharmacology Society Meeting

Our latest technologies were widely showcased at the SPS Annual Meeting, held between Sep 30 to Oct 3, an industry conference attended by many decision-makers in the safety pharmacology space, both from pharma and the US Food & Drug Administration (FDA), in oral presentations, scientific posters and a brand new modular bioreactor display at our exhibition booth.

24
Sep
2018
Novoheart Recruits Notable Pharma Industry Executive, Bernard Fermini, Ph.D. as Chief R&D Officer

Novoheart is proud to announce today that it has appointed Bernard Fermini, Ph.D. as Chief Research & Development Officer. With his well-recognized stature in the safety pharmacology community, the addition of Dr. Fermini to the team further validates Novoheart's revolutionary technology to prospective clients who are seeking to implement it into their drug discovery and screening processes.

12
Sep
2018
Novoheart is selected as one of 'Top 50 of Innovative Biotechnology Enterprises in Greater Bay Area'

Novoheart is proud to announce that we have been successfully selected as one of "The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area 2018" , as one of 5 enterprises from Hong Kong on the list.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!